Share on StockTwits

A number of stock research firms have changed their ratings and price targets for AstraZeneca plc (NYSE: AZN) during the last seven days:

  • AstraZeneca plc was upgraded by analysts at Danske to a “hold” rating.
  • AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital.
  • AstraZeneca plc had its “hold” rating reaffirmed by analysts at Beaufort Securities.
  • AstraZeneca plc had its “equal weight” rating reaffirmed by analysts at Barclays. They now have a $40.00 price target on the stock, up previously from $38.00.
  • AstraZeneca plc had its “hold” rating reaffirmed by analysts at Deutsche Bank.
  • AstraZeneca plc was downgraded by analysts at Societe Generale from a “hold” rating to a “sell” rating.
  • AstraZeneca plc is now covered by analysts at Bank of America. They set a “neutral” rating on the stock.
  • AstraZeneca plc was downgraded by analysts at Kepler Capital Markets from a “hold” rating to a “reduce” rating.
  • AstraZeneca plc had its “hold” rating reaffirmed by analysts at Jefferies Group.
  • AstraZeneca plc had its price target lowered by analysts at ING Group from $84.00 to $74.00.
  • AstraZeneca plc had its “hold” rating reaffirmed by analysts at Beaufort Securities.

Shares of AstraZeneca plc (NYSE:AZN) opened at 71.29 on Friday. AstraZeneca plc has a 52-week low of $46.87 and a 52-week high of $82.68. The stock’s 50-day moving average is $72.91 and its 200-day moving average is $64.54. The company has a market cap of $89.897 billion and a price-to-earnings ratio of 43.63.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.